{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-26-000053","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.719549+00:00","generated_at":"2026-05-14T23:39:32.966257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance","bullets":["Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.","Reported diluted EPS $0.47, adjusted $0.75 vs $0.92 in Q1 '25 (-18%).","Reaffirmed FY26 revenue guidance $59.5-62.5B and adj EPS $2.80-3.00.","Positive Phase 3 readouts for Elrexfio (RRMM), Padcev (MIBC), Talzenna+Xtandi, Lyme vaccine 73-75% efficacy.","Exited ViiV Healthcare for $1.875B; Vyndamax patent settlement extends to 2031; GLP-1 collaboration in China for ecnoglutide."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-26-000053","json":"https://secwatch.observer/filing/0000078003-26-000053.json","markdown":"https://secwatch.observer/filing/0000078003-26-000053.md","text":"https://secwatch.observer/filing/0000078003-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/0000078003-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:39:32.966257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e111b24f39e531b393580ff1cbd99657cfb566e7","claim":"PFIZER INC reported the first quarter of 2026 results: revenue $14,451, net income 2,687, EPS 0.47. Guidance reaffirmed.","evidence_excerpt":"rates (5) . Results for the first quarter of 2026 and 2025 (6) are summarized below. ($ in millions, except per share amounts) First-Quarter 2026 2025 % Change Revenues $ 14,451 $ 13,715 5% Reported (3) Net Income 2,687 2,967 (9%) Reported (3) Diluted EPS 0.47 0.52 (10%) Adjusted (4) Income 4,290 5,237 (18%) Adjusted (4) Diluted EPS 0.75 0.92 (18%)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/0000078003-26-000053-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Revenue","value":"$14,451"},{"label":"Net income","value":"2,687"},{"label":"EPS","value":"0.47"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}